H1N1
> The latest numbers on swine flu vaccinations in the U.S.: 40 percent of parents had their children vaccinated and 70 million Americans in total have been vaccinated. A total of 229 million doses have been ordered, but 44 percent of adults believe the pandemic is over. 100 percent of health officials say those people are absolutely wrong. Report
> Australia is being warned to prepare for a second wave of swine flu cases. Story
> Sanofi-Aventis has moved up the expiration date for its swine flu vaccine in order to guard against any loss of potency. Report
> SciClone says new tests show that its adjuvant significantly increased the effectiveness of a swine flu vaccine. Report
Vaccine Market
> Merck and GlaxoSmithKline could get a boost from New York lawmakers. Two bills working their way through the New York State Legislature would mandate that schoolchildren receive a human papillomavirus vaccine, even without a parent's consent. Story
> Novavax says it has ended discussions with Spain's Rovi Pharmaceuticals aimed at collaborating on producing virus-like particle vaccines in the country. Report
> GlaxoSmithKline's Cervarix was approved in Canada to guard against the human papillomavirus. Report
> New York City is urging young adults to get vaccinated against the mumps. Story
> A new report suggests that far too few of the elderly get the pneumonia vaccine they need. Story
Vaccine Research
> Dynavax is planning to recruit 2,000 patients to test its hepatitis B vaccine Heplisav. The data should be available in the first half of 2011. Story
> Tulane University won a five-year, $15 million federal contract to develop a new vaccine for Lassa fever. The virus is considered a bioterrorism threat. Report
> Nabi has qualified for an $8 million milestone payment from GlaxoSmithKline related to their deal on the PentaStaph vaccine. Report
> Scotland's Big DNA has gained 2 million pounds of new financing to back their work on new vaccines. Story
> A new vaccine to prevent malaria infection has shown promise to protect the most vulnerable patients--young children--against the disease, according to an international team of researchers led by the University of Maryland School of Medicine's Center for Vaccine Development and the Malaria Research and Training Center at the University of Bamako in Mali, West Africa. Release
> GeoVax Labs provided an update on its vaccine trials progress. Report